This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kandzari, D. E. Articles by Teirstein, P. S. Search for Related Content PubMed Articles by Kandzari, D. E. Articles by Teirstein, P. S.

Identifying the "Optimal" Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization

David E. Kandzari, MD^_*,_*, Dominick J. Angiolillo, MD, PhD, Matthew J. Price, MD^_*, Paul S. Teirstein, MD^_*

^_* Division of Cardiovascular Disease, Scripps Clinic, La Jolla, California
University of Florida College of Medicine-Jacksonville, Jacksonville, Florida

^_* Reprint requests and correspondence: Dr. David E. Kandzari, Division of Cardiovascular Disease, Scripps Green Clinic, Maildrop S1056, 10666 North Torrey Pines Road, La Jolla, California 92037 (Email: kandzari.david{at}scrippshealth.org).

Uncertainty regarding the appropriate duration of dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine challenges every clinician involved in the care of patients considered for or treated with drug-eluting stents (DES). Despite guideline recommendations for extended (12 months) DAPT following percutaneous coronary revascularization with DES, few data are available to guide clinical decision-making beyond consensus opinion. Yet considering the clinical implications of stent thrombosis (ST) and its unpredictability in late occurring events, comprehensive assessment of the relationship between DAPT duration and ST over the long-term is a focus for DES-related clinical trials and an essential public health measure. Despite the potential for prolonged DAPT to reduce late-term cardiovascular events related to the progression of atherosclerosis, few studies have formally examined the safety and efficacy of extended DAPT and its impact on late ST events. The purpose of this paper is to appraise the existing evidence regarding the relationship between long-term DAPT and late cardiovascular events; address outstanding (and unstudied) dilemmas related to DAPT in DES-treated patients; and propose considerations for both trial design and clinical practice.

Key Words: stent thrombosis • dual antiplatelet therapy • drug-eluting stents

Abbreviations and Acronyms   BMS = bare-metal stent(s)   DAPT = dual antiplatelet therapy   DES = drug-eluting stent(s)   MI = myocardial infarction   PCI = percutaneous coronary intervention   ST = stent thrombosis

This article has been cited by other articles:

				D. E. Kandzari, C. S. Barker, M. B. Leon, L. Mauri, W. Wijns, J. Fajadet, and R. Mehran Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents J. Am. Coll. Cardiol. Intv., October 1, 2011; 4(10): 1119 - 1128. [Abstract] [Full Text] [PDF]